๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 33 Nanjing 15 Shanghai 14 Guangzhou 14 Wuhan 11
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing33 Nanjing15 Shanghai14 Guangzhou14 Wuhan11
All 48 locations
Target enrolment
to

Trials with a site in Nanjing

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
SNC116 Therapy for Refractory Systemic Lupus Erythematosus
NCT07748156Systemic Lupus Erythematosus
DrugSNC116
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase EARLY_PHASE1
28
Nanjing
2026-10
Recruiting
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
NCT07558850Rheumatoid Arthritis, Dermatomyositis, Systemic Lupus Erythematosus, Systemic Sclerosis
The First Affiliated Hospital with Nanjing Medical University
Not applicable
72
Nanjing
2026-05-10
By invitation
CHT105 for the Treatment of Refractory Lupus Nephritis
NCT07517536Systemic Lupus Erythematosus, Lupus Nephritis
DrugCHT105
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
14
Nanjing
2026-04-22
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
Boehringer Ingelheim
Phase 2
405
Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai
2026-04-20
Recruiting
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
NCT07318259Systemic Lupus Erythematosus
Chongqing Precision Biotech Co., Ltd
Phase 1
18
Nanjing
2026-01-26
Recruiting
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07331467Systemic Lupus Erythematosus
Chongqing Precision Biotech Co., Ltd
Phase 1
18
Nanjing
2026-01
Recruiting
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
NCT07323173Systemic Lupus Erythematosus
Nanjing Leads Biolabs Co.,Ltd
Phase 1
117
Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan
2025-12-16
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
AstraZeneca
Phase 1
48
Beijing, Chengdu, Nanjing
2025-12-02
Recruiting
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
NCT07109986Systemic Lupus Erythematosus, Lupus Nephritis
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
21
Nanjing
2025-10-27
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
550
Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi
2024-05-21
Not yet open
A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)
NCT06340490Systemic Lupus Erythematosus
Guangdong Ruishun Biotech Co., Ltd
Phase 1
24
Beijing, Nanjing, Shanghai
2024-05-15
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
AstraZeneca
Phase 3
100
Beijing, Changchun, Changsha, Dongguan, Nanjing, Shanghai, Suzhou, Wenzhou
2024-03-14
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
436
Guangzhou, Shantou, Haikou, Zhuzhou, Nanjing, Suzhou, Nanchang, Pingxiang
2023-03-02
Active, closed
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327Systemic Lupus Erythematosus
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
379
Baotou, Beijing, Changchun, Guangzhou, Haikou, Luoyang, Nanchang, Nanjing
2022-09-16
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Beijing, Shenzhen, Nanjing, Suzhou, Changchun, Dalian, Jinan, Jining
2021-10-11
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies with a site in Nanjing that also match the filters currently applied.

How many clinical trials are recruiting in Nanjing?

9 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanjing), 15 studies
PhaseStudiesRecruitingShare
Phase 16540%
Phase 23120%
Phase 33220%
Not applicable2113.3%
Phase EARLY_PHASE1106.7%

Most active sponsors

Lead sponsors with the most studies (Nanjing)
Lead sponsorStudiesRecruiting
AstraZeneca22
Chongqing Precision Biotech Co., Ltd22
Novartis Pharmaceuticals21
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School20
Beeline Medicines Corporation10
Boehringer Ingelheim11
Guangdong Ruishun Biotech Co., Ltd10
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany10
Nanjing IASO Biotechnology Co., Ltd.11
Nanjing Leads Biolabs Co.,Ltd11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.